Mutational profile of oropharyngeal squamous cell carcinoma in relation to HPV, tobacco smoking and prognosis with validation in the DAHANCA 19 randomized trial
DOI:
https://doi.org/10.2340/1651-226X.2025.44042Keywords:
Squamous Cell Carcinoma of Head and Neck, Radiotherapy, Human Papillomavirus, BiomarkersAbstract
Background and purpose: This study investigated prognostic biomarkers in oropharyngeal squamous cell carcinoma (OPSCC), with a focus on tumors related to human papillomavirus (HPV) infection and potential molecular effects of tobacco smoking, as smokers with HPV+ OPSCC often have poorer outcomes.
Patients/material and methods: We first analyzed 56 previously untreated OPSCC patients (exploration cohort), assessing HPV status, gene expression related to hypoxia, tumor subtype, and radiosensitivity, together with next-generation sequencing (NGS) of cancer-related genes. A custom NGS panel was subsequently designed and validated in 162 patients from the DAHANCA 19 randomized controlled trial (RCT), all treated with curative (chemo-)radiotherapy.
Results:In the exploration cohort (40 HPV+, 79%), the most common molecular events in HPV+ tumors were PIK3CA and ATR mutations and chromosome 3q amplification. ATR and CREBBP mutations occurred more often in heavy smokers (>10 pack-years), but these associations were not confirmed in the DAHANCA 19 cohort. No specific smoking-related mutational signature or link to TP53 mutations was observed.
In the DAHANCA 19 cohort, 17 locoregional failures (LRF) occurred among 128 HPV+ patients. No unifying molecular features were identified. However, mutations in NFE2L2 and CASP8, as well as amplifications of 3q genes (BCL6, SOX2), were associated with LRF.
Interpretation: In HPV+ OPSCC, only few molecular alterations appear to act as drivers or prognostic biomarkers. Importantly, no molecular features of tobacco smoking exposure were identified, and the mechanism behind the worse prognosis in smokers remains unclear.
Downloads
References
Zumsteg ZS, Luu M, Rosenberg PS, Elrod JK, Bray F, Vaccarella S, et al. Global epidemiologic patterns of oropharyngeal cancer incidence trends. J Natl Cancer Inst. 2023;115(12):1544–54.
https://doi.org/10.1093/jnci/djad169 DOI: https://doi.org/10.1093/jnci/djad169
Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022;19(5):306–27.
https://doi.org/10.1038/s41571-022-00603-7 DOI: https://doi.org/10.1038/s41571-022-00603-7
Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27(12):1992–8.
https://doi.org/10.1200/JCO.2008.20.2853 DOI: https://doi.org/10.1200/JCO.2008.20.2853
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.
https://doi.org/10.1056/NEJMoa0912217 DOI: https://doi.org/10.1056/NEJMoa0912217
Lassen P, Lacas B, Pignon J, Trotti A, Zackrisson B, Zhang Q, et al. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: the MARCH-HPV project. Radiother Oncol. 2018;126(1):107–15.
https://doi.org/10.1016/j.radonc.2017.10.018 DOI: https://doi.org/10.1016/j.radonc.2017.10.018
Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, et al. Molecular classification identifies a subset of human papillomavirus – associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006;24(5):736–47.
https://doi.org/10.1200/JCO.2004.00.3335 DOI: https://doi.org/10.1200/JCO.2004.00.3335
Zevallos JPP, Yim E, Brennan P, Liu AYY, Taylor JMM, Weissler M, et al. Molecular profile of human papillomavirus positive oropharyngeal squamous cell carcinoma stratified by smoking status. Int J Radiat Oncol Biol Phys. 2016;94(4):864.
https://doi.org/10.1016/j.ijrobp.2015.12.022 DOI: https://doi.org/10.1016/j.ijrobp.2015.12.022
Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–82.
https://doi.org/10.1038/nature14129 DOI: https://doi.org/10.1038/nature14129
Gillison ML, Akagi K, Xiao W, Jiang B, Pickard RKL, Li J, et al. Human papillomavirus and the landscape of secondary genetic alterations in oral cancers. Genome Res. 2019;29(1):1–17.
https://doi.org/10.1101/gr.241141.118 DOI: https://doi.org/10.1101/gr.241141.118
Toustrup K, Sørensen BS, Metwally MAH, Tramm T, Mortensen LS, Overgaard J, et al. Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials. Acta Oncol. 2016;55(9–10):1091–8.
https://doi.org/10.3109/0284186X.2016.1167959 DOI: https://doi.org/10.3109/0284186X.2016.1167959
Lilja-Fischer JK, Ulhøi BP, Alsner J, Stougaard M, Thomsen MS, Busk M, et al. Characterization and radiosensitivity of HPV-related oropharyngeal squamous cell carcinoma patient-derived xenografts. Acta Oncol. 2019;58(10):1489–94.
https://doi.org/10.1080/0284186X.2019.1660802 DOI: https://doi.org/10.1080/0284186X.2019.1660802
Eriksen JG, Maare C, Johansen J, Primdahl H, Bratland Å, Kristensen CA, et al. DAHANCA19: a randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck. Radiother Oncol. 2025;208:110899.
https://doi.org/10.1016/j.radonc.2025.110899 DOI: https://doi.org/10.1016/j.radonc.2025.110899
Saksø M, Andersen E, Bentzen J, Andersen M, Johansen J, Primdahl H, et al. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma. Acta Oncol. 2019;58(10):1495–501.
https://doi.org/10.1080/0284186X.2019.1658897 DOI: https://doi.org/10.1080/0284186X.2019.1658897
Overgaard J, Jovanovic A, Godballe C, Grau Eriksen J. The Danish head and neck cancer database. Clin Epidemiol. 2016;8:491–6.
https://doi.org/10.2147/CLEP.S103591 DOI: https://doi.org/10.2147/CLEP.S103591
Toustrup K, Sørensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J, et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 2011;71(17):5923–31.
https://doi.org/10.1158/0008-5472.CAN-11-1182 DOI: https://doi.org/10.1158/0008-5472.CAN-11-1182
Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. 2016;18(2):202–11.
https://doi.org/10.1016/S1470-2045(16)30648-9 DOI: https://doi.org/10.1016/S1470-2045(16)30648-9
Keck MK, Zuo Z, Khattri A, Stricker TP, Brown C, Imanguli M, et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2014;21(4):870–82.
https://doi.org/10.1158/1078-0432.CCR-14-2481 DOI: https://doi.org/10.1158/1078-0432.CCR-14-2481
Lassen P, Overgaard J. Scoring and classification of oropharyngeal carcinoma based on HPV-related p16-expression. Radiother Oncol. 2012;105(2):269–70.
https://doi.org/10.1016/j.radonc.2012.09.017 DOI: https://doi.org/10.1016/j.radonc.2012.09.017
Lassen P, Schou M, Overgaard J, Alsner J. Correlation and prognostic impact of human papilloma virus and p16-expression in advanced hypopharynx and larynx cancer treated with definitive radiotherapy. Acta Oncol. 2021;60(5):646–8.
https://doi.org/10.1080/0284186X.2021.1885059 DOI: https://doi.org/10.1080/0284186X.2021.1885059
Lilja-Fischer JK, Kristensen MH, Lassen P, Steiniche T, Tramm T, Stougaard M, et al. HPV testing versus p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: results from the DAHANCA 19 study. Acta Oncol. 2023;62(11):1384–8.
https://doi.org/10.1080/0284186X.2023.2266127 DOI: https://doi.org/10.1080/0284186X.2023.2266127
cBioPortal - Head and Neck Squamous Cell Carcinoma (TCGA, PanCancer Atlas). [Web page] [Cited date: 18 dec 2023] Available from http://www.cbioportal.org/study/summary?id=hnsc_tcga_pan_can_atlas_2018
Mirghani H, Lacroix L, Rossoni C, Sun R, Aupérin A, Casiraghi O, et al. Does smoking alter the mutation profile of human papillomavirus–driven head and neck cancers? Eur J Cancer. 2018;94:61–9.
https://doi.org/10.1016/j.ejca.2018.02.013 DOI: https://doi.org/10.1016/j.ejca.2018.02.013
Hoff CM, Grau C, Overgaard J. Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma – a prospective study. Radiother Oncol. 2012;103(1):38–44.
https://doi.org/10.1016/j.radonc.2012.01.011 DOI: https://doi.org/10.1016/j.radonc.2012.01.011
Steiniche T, Eriksen JG, Lilja-Fischer JK, Georgsen J, Vo P-T, Busch-Sørensen M, et al. Programmed death-ligand 1 (PD-L1) expression and HPV-associated p16 in oropharyngeal squamous cell carcinoma (OSCC) treated with primary curative radiotherapy (RT). Ann Oncol. 2018;29(8):109.
https://doi.org/10.1093/annonc/mdy287.038 DOI: https://doi.org/10.1093/annonc/mdy287.038
Wahle BM, Zolkind P, Ramirez RJ, Skidmore ZL, Anderson SR, Mazul A, et al. Integrative genomic analysis reveals low T-cell infiltration as the primary feature of tobacco use in HPV-positive oropharyngeal cancer. iScience. 2022;25(5):104216.
https://doi.org/10.1016/j.isci.2022.104216 DOI: https://doi.org/10.1016/j.isci.2022.104216
Kemnade JO, Elhalawani H, Castro P, Yu J, Lai S, Ittmann M, et al. CD8 infiltration is associated with disease control and tobacco exposure in intermediate-risk oropharyngeal cancer. Sci Rep. 2020;10(1):1–10.
https://doi.org/10.1038/s41598-019-57111-5 DOI: https://doi.org/10.1038/s41598-019-57111-5
Mehanna H, Rapozo D, von Zeidler SV, Harrington KJ, Winter SC, Hartley A, et al. Developing and validating a multivariable prognostic-predictive classifier for treatment escalation of oropharyngeal squamous cell carcinoma: the PREDICTR-OPC study. Clin Cancer Res. 2024;30(2):356–67.
https://doi.org/10.1158/1078-0432.CCR-23-1013 DOI: https://doi.org/10.1158/1078-0432.CCR-23-1013
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Jacob Lilja-Fischer, Morten Horsholt Kristensen , Pernille Lassen, Torben Steiniche, Trine Tramm, Magnus Stougaard, Anders Frederiksen, Benedicte Ulhøi, Jan Alsner, Kasper Toustrup, Christian Maare, Jørgen Johansen, Hanne Primdahl, Claus Andrup Kristensen, Maria Andersen, Jesper Grau Eriksen, Jens Overgaard
This work is licensed under a Creative Commons Attribution 4.0 International License.
